Physician profile
Reena Enaker
NPI 1124388483
$1,956.30
in general payments reported to CMS, 2019-2025
28 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.52 · 2023: $16.19 · 2024: $1,235 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,922.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,921.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $377.73 | 2024-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $217.87 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.81 | 2024-2025 | Jardiance |
| Abbvie INC. | $167.15 | 2025 | |
| Vanda Pharmaceuticals INC. | $115.97 | 2024-2025 | Fanapt, Hetlioz |
| Novo Nordisk INC | $104.55 | 2019-2024 | Wegovy |
| Dynavax Technologies Corporation | $77.53 | 2024-2025 | Heplisav-B |
| Axsome Therapeutics, INC. | $72.45 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $72.13 | 2024-2025 | Trelegy Ellipta |
| Amgen INC. | $53.12 | 2024-2025 | Evenity, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $49.37 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $48.75 | 2024-2025 | Unithroid |
| Astrazeneca Pharmaceuticals LP | $42.78 | 2024 | Farxiga |
| Gilead Sciences, INC. | $42.22 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.19 | 2024-2025 | Caplyta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $34.37 | 2023-2024 | Cologuard Collection Kit |
| Nevro Corp. | $29.86 | 2024 | Senza |
| Xeris Pharmaceuticals, INC. | $24.86 | 2024 | Gvoke Hypopen |
| Dexcom, INC. | $20.73 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $20.05 | 2024 | |
| Alnylam Pharmaceuticals INC. | $19.96 | 2025 | Givlaari |
| Abbott Laboratories | $19.61 | 2024 | Freestyle Libre 3 |
| Verona Pharma, INC. | $18.70 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $17.67 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Sage Therapeutics, LLC | $17.34 | 2025 | Zurzuvae |
| Astellas Pharma US INC | $16.49 | 2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $15.50 | 2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $14.54 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reena Enaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.